These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35104636)

  • 1. The biotechnology sector in a latecomer country: The case of Poland.
    Szczygielski K; Lewkowicz J; Michałek JJ
    N Biotechnol; 2022 May; 68():97-107. PubMed ID: 35104636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current state and prospects of biotechnology in Central and Eastern European countries. Part I: Visegrad countries (CZ, H, PL, SK).
    Dettenhofer M; Ondrejovič M; Vásáry V; Kaszycki P; Twardowski T; Stuchlík S; Turňa J; Dundar M; Gartland KMA; Miertuš S
    Crit Rev Biotechnol; 2019 Feb; 39(1):114-136. PubMed ID: 30372626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioeconomy development factors in the European Union and Poland.
    Woźniak E; Tyczewska A; Twardowski T
    N Biotechnol; 2021 Jan; 60():2-8. PubMed ID: 32835869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicine and pharmacy--facts and myths about the development of an innovative pharmaceutical industry in Poland.
    Kubiak W
    Sci Eng Ethics; 2005 Jan; 11(1):41-51. PubMed ID: 15726998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact Reimbursement Act on the pharmaceutical market in Poland].
    Giermaziak W
    Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bioeconomy in Poland within the context of the European Union.
    Woźniak E; Twardowski T
    N Biotechnol; 2018 Jan; 40(Pt A):96-102. PubMed ID: 28647548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.
    Fernald KD; Pennings HP; van den Bosch JF; Commandeur HR; Claassen E
    PLoS One; 2017; 12(2):e0172488. PubMed ID: 28231332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.
    Jung YL; Hwang J; Yoo HS
    Global Health; 2020 Sep; 16(1):80. PubMed ID: 32912258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care innovation: progress report and focus on biotechnology.
    Read JL; Lee KB
    Health Aff (Millwood); 1994; 13(3):215-25. PubMed ID: 7927152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the pharmaceutical market in Poland after accession to the European Union.
    Willert PL
    Eur J Health Econ; 2007 Dec; 8(4):347-57. PubMed ID: 17186200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Just how good an investment is the biopharmaceutical sector?
    Thakor RT; Anaya N; Zhang Y; Vilanilam C; Siah KW; Wong CH; Lo AW
    Nat Biotechnol; 2017 Dec; 35(12):1149-1157. PubMed ID: 29220034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Polish medical students are socialised to cooperate with the pharmaceutical industry: a focus group study of the importance of informal, hidden and null curricula.
    Makowska M
    Health Sociol Rev; 2022 Mar; 31(1):81-95. PubMed ID: 33784212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Labor Costs Affect Innovation Output in Pharmaceutical Companies: Evidence from China.
    Chen Y; He Q; Wang T
    Inquiry; 2024; 61():469580241246965. PubMed ID: 38726640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. China: current trends in pharmaceutical drug discovery.
    Luo Y
    IDrugs; 2008 Apr; 11(4):279-82. PubMed ID: 18379963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs.
    Kang KN; Lee YS
    Biotechnol Lett; 2008 Oct; 30(10):1699-704. PubMed ID: 18506395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the economic situation of the South East European pharmaceutical industry.
    Milenković J; Lakić D
    J Med Econ; 2020 Sep; 23(9):932-939. PubMed ID: 32349564
    [No Abstract]   [Full Text] [Related]  

  • 19. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Nutrition and Health Claims Regulation (EC) No. 1924/2006: What is the impact on innovation in the EU food sector?
    Khedkar S; Bröring S; Ciliberti S
    Int J Food Sci Nutr; 2017 Feb; 68(1):10-17. PubMed ID: 27484471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.